Hims Semaglutide is a compounded medication containing semaglutide, the active ingredient found in the FDA-approved weight loss drug Wegovy, offered through the Hims & Hers telehealth platform
GBM 2012.2 displayed 4- and 2-fold higher glucose-derived synthesis of serine and glycine, respectively, compared to GBM 1919, which showed low levels of baseline ser/gly synthesis, suggesting dependency on serine and glycine uptake (Fig
So obesity increases inflammation, increases adipose tissue malfunction, which in turn increases insulin resistance, and therefore adding up to this cycle
The post hoc analysis of pooled data from the Semaglutide Treatment Effect in People with Obesity (STEP) 1, 2, 3, and 5 trials indicated that semaglutide treatment at 2.4 mg did not increase the risk of depressive symptoms or suicidal ideation compared to placebo, while demonstrating a statistically significant yet clinically negligible decrease in depressive symptoms [75]